TScan Therapeutics (TCRX) Competitors

$0.98 -0.02 (-2.30%)

As of 03:37 PM Eastern

TCRX vs. FHTX, LENZ, IKT, RNAC, and VYGR

Should you buy TScan Therapeutics stock or one of its competitors? MarketBeat compares TScan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TScan Therapeutics include Foghorn Therapeutics (FHTX), LENZ Therapeutics (LENZ), Inhibikase Therapeutics (IKT), Cartesian Therapeutics (RNAC), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does TScan Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Foghorn Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Foghorn Therapeutics has a net margin of -266.88% compared to TScan Therapeutics' net margin of -1,360.61%. Foghorn Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Foghorn Therapeutics has higher revenue and earnings than TScan Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	6.89	-$74.28M	-$1.16	N/A
TScan Therapeutics	$9.14M	6.99	-$129.77M	-$0.96	N/A

Foghorn Therapeutics currently has a consensus price target of $11.43, indicating a potential upside of 214.84%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 514.12%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Foghorn Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 1 mentions for Foghorn Therapeutics and 0 mentions for TScan Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.78 beat TScan Therapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Foghorn Therapeutics	Positive
TScan Therapeutics	Neutral

Summary

Foghorn Therapeutics beats TScan Therapeutics on 12 of the 17 factors compared between the two stocks.

How does TScan Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

LENZ Therapeutics has higher revenue and earnings than TScan Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$20.99M	10.04	-$82.13M	-$3.60	N/A
TScan Therapeutics	$9.14M	6.99	-$129.77M	-$0.96	N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 11 more articles in the media than TScan Therapeutics. MarketBeat recorded 11 mentions for LENZ Therapeutics and 0 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.00 beat LENZ Therapeutics' score of -0.54 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
LENZ Therapeutics	Negative
TScan Therapeutics	Neutral

LENZ Therapeutics has a net margin of -519.30% compared to TScan Therapeutics' net margin of -1,360.61%. LENZ Therapeutics' return on equity of -46.82% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

LENZ Therapeutics currently has a consensus target price of $29.80, suggesting a potential upside of 343.45%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 514.12%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LENZ Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

LENZ Therapeutics beats TScan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Inhibikase Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Inhibikase Therapeutics' return on equity of -41.31% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Inhibikase Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	799.80	-$48.26M	-$0.43	N/A
TScan Therapeutics	$9.14M	6.99	-$129.77M	-$0.96	N/A

In the previous week, Inhibikase Therapeutics had 4 more articles in the media than TScan Therapeutics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 0 mentions for TScan Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat TScan Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
TScan Therapeutics	Neutral

Inhibikase Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Inhibikase Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 249.21%. TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 514.12%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks.

How does TScan Therapeutics compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cartesian Therapeutics presently has a consensus target price of $33.00, indicating a potential upside of 427.58%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 514.12%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cartesian Therapeutics had 12 more articles in the media than TScan Therapeutics. MarketBeat recorded 12 mentions for Cartesian Therapeutics and 0 mentions for TScan Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.30 beat TScan Therapeutics' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cartesian Therapeutics	Neutral
TScan Therapeutics	Neutral

Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

TScan Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	65.63	-$130.30M	-$5.90	N/A
TScan Therapeutics	$9.14M	6.99	-$129.77M	-$0.96	N/A

TScan Therapeutics has a net margin of -1,360.61% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Summary

Cartesian Therapeutics beats TScan Therapeutics on 9 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Voyager Therapeutics has a net margin of -319.61% compared to TScan Therapeutics' net margin of -1,360.61%. Voyager Therapeutics' return on equity of -55.97% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Voyager Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Voyager Therapeutics has higher revenue and earnings than TScan Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	5.19	-$119.72M	-$1.97	N/A
TScan Therapeutics	$9.14M	6.99	-$129.77M	-$0.96	N/A

In the previous week, Voyager Therapeutics had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Voyager Therapeutics and 0 mentions for TScan Therapeutics. Voyager Therapeutics' average media sentiment score of 0.27 beat TScan Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
TScan Therapeutics	Neutral

Voyager Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 376.19%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 514.12%. Given TScan Therapeutics' higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Voyager Therapeutics beats TScan Therapeutics on 11 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$63.98M	$3.26B	$6.27B	$12.13B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-1.02	18.70	20.61	25.11
Price / Sales	6.99	281.88	578.26	91.48
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.45	6.59	9.72	6.63
Net Income	-$129.77M	$24.30M	$3.55B	$335.73M
7 Day Performance	-15.04%	-3.36%	-1.89%	-1.80%
1 Month Performance	-17.90%	-7.67%	-3.77%	-1.69%
1 Year Performance	-21.21%	52.30%	29.58%	27.59%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	3.3166 of 5 stars	$0.98 -2.3%	$6.00 +514.1%	-19.4%	$63.98M	$9.14M	N/A	100
FHTX Foghorn Therapeutics	2.9747 of 5 stars	$4.36 +0.7%	$11.13 +155.2%	-13.8%	$255.98M	$30.91M	N/A	120
LENZ LENZ Therapeutics	2.501 of 5 stars	$8.11 -18.9%	$31.00 +282.4%	-74.3%	$255.82M	$19.09M	N/A	110
IKT Inhibikase Therapeutics	2.3388 of 5 stars	$1.94 -4.7%	$5.50 +184.2%	N/A	$255.54M	N/A	N/A	6	Positive News Earnings Report
RNAC Cartesian Therapeutics	3.1866 of 5 stars	$8.61 +0.9%	$33.00 +283.3%	-32.8%	$251.99M	$2.80M	N/A	64

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. FHTX, LENZ, IKT, RNAC, and VYGR

How does TScan Therapeutics compare to Foghorn Therapeutics?

Summary

How does TScan Therapeutics compare to LENZ Therapeutics?

Summary

How does TScan Therapeutics compare to Inhibikase Therapeutics?

Summary

How does TScan Therapeutics compare to Cartesian Therapeutics?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. FHTX, LENZ, IKT, RNAC, and VYGR

How does TScan Therapeutics compare to Foghorn Therapeutics?

Do institutionals and insiders believe in FHTX or TCRX?

Which has more risk & volatility, FHTX or TCRX?

Is FHTX or TCRX more profitable?

Which has stronger valuation and earnings, FHTX or TCRX?

Do analysts rate FHTX or TCRX?

Does the media favor FHTX or TCRX?

Summary

How does TScan Therapeutics compare to LENZ Therapeutics?

Which has stronger valuation & earnings, LENZ or TCRX?

Do institutionals & insiders believe in LENZ or TCRX?

Does the media prefer LENZ or TCRX?

Is LENZ or TCRX more profitable?

Do analysts prefer LENZ or TCRX?

Which has more risk & volatility, LENZ or TCRX?

Summary

How does TScan Therapeutics compare to Inhibikase Therapeutics?

Is IKT or TCRX more profitable?

Which has higher earnings and valuation, IKT or TCRX?

Does the media prefer IKT or TCRX?

Which has more volatility & risk, IKT or TCRX?

Do analysts prefer IKT or TCRX?

Do institutionals and insiders believe in IKT or TCRX?

Summary

How does TScan Therapeutics compare to Cartesian Therapeutics?

Do insiders and institutionals believe in RNAC or TCRX?

Do analysts prefer RNAC or TCRX?

Does the media favor RNAC or TCRX?

Which has more volatility and risk, RNAC or TCRX?

Which has preferable earnings & valuation, RNAC or TCRX?

Is RNAC or TCRX more profitable?

Summary

How does TScan Therapeutics compare to Voyager Therapeutics?

Is VYGR or TCRX more profitable?

Which has more risk & volatility, VYGR or TCRX?

Do institutionals and insiders hold more shares of VYGR or TCRX?

Which has better earnings & valuation, VYGR or TCRX?

Does the media prefer VYGR or TCRX?

Do analysts rate VYGR or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools